Trial
NCT03374852
CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Collaborators
Cornerstone Pharmaceuticals
Condition
Pancreatic Ductal Adenocarcinoma
Intervention
CPI-613
Why stopped
PI Left institution on 8/6/2018 and study has been final reported with IRB. Never opened to accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-04-29